Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus
N/A
30 Years
Both
Leukemia
Trial Information
Feasibility of Minimal Residual Disease (MRD) Determination in Pediatric B-Lineage ALL Using Deep Sequencing of the Immunoglobulin Heavy Chain Locus
OBJECTIVES:
- Assess the feasibility of minimal residual disease (MRD) determination in pediatric
B-lineage acute lymphoblastic leukemia (ALL) using deep sequencing of the
immunoglobulin heavy chain locus.
OUTLINE: Archived blood and tumor tissue samples are analyzed for MDR using deep sequencing
of immunoglobulin heavy chain locus. MDR quantification results are then compared with the
flow cytometry reference methods used in COG studies.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Samples from patients registered on the Children Oncology Group (COG)-AALL08B1
protocol and stored in the Hematopathology Laboratory at the University of Washington
- Pretreatment and after induction therapy samples
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Type of Study:
Observational
Study Design:
N/A
Outcome Measure:
Sensitivity of deep sequencing of the immunoglobulin heavy chain locus in determining MRD in B-lineage ALL
Principal Investigator
Brent Wood, MD, PhD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Seattle Cancer Care Alliance
Authority:
United States: Federal Government
Study ID:
CDR0000735591
NCT ID:
NCT01629745
Start Date:
June 2012
Completion Date:
Related Keywords:
- Leukemia
- B-cell childhood acute lymphoblastic leukemia
- untreated childhood acute lymphoblastic leukemia
- Leukemia
- Neoplasm, Residual
Name | Location |
|---|
